ACADIA Pharmaceuticals stock (US0042251084): Biotech decline amid CNS focus
ACADIA Pharmaceuticals (ACAD) has seen a 19.2% stock decline year-to-date in 2026, dropping to $21.57 per share amidst competitive pressures in the central nervous system (CNS) disorder treatment market. Despite this, analysts largely maintain a "Moderate Buy" rating with an average price target of $31.00, suggesting a potential 43.7% upside. The company remains profitable with a 34.30% net margin, and its decline is attributed more to broader sector volatility than company-specific issues.
MAY 11·Simply Wall Street→
A Look At ACADIA Pharmaceuticals (ACAD) Valuation After Mixed Q1 2026 Results And EU Trofinetide Setback
ACADIA Pharmaceuticals (ACAD) reported mixed Q1 2026 results with 10% revenue growth but weaker earnings and a setback for trofinetide in Europe. Despite these challenges, ACADIA's stock shows a 33.28% one-year return and analysts see the company as undervalued with a fair value of $28.75. The valuation hinges on balancing clinical ambition with financial discipline and disciplined execution in its specialized neurology and rare disease focus.
MAR 21·Stock Titan→
ACADIA (NASDAQ: ACAD) director Jonathan Poole submits initial Form 3 insider report
Jonathan Poole, a director at ACADIA PHARMACEUTICALS INC (NASDAQ: ACAD), has filed an initial Statement of Beneficial Ownership (Form 3). This filing signifies his official status as a director for SEC insider reporting purposes but does not involve any stock transactions, purchases, or sales. The Form 3 details his directorship and confirms no beneficial ownership of non-derivative or derivative securities at the time of the filing.
